GlobeNewswire - Industry News on Pharmaceuticals Contains the last 20 releases uuid:8f3c45ed-7282-4d04-a5a7-dd6d43c0ca7f;id=11660 2021-02-05T22:00:00Z newsdesk@globenewswire.com (NewsDesk) http://www.10gbhost.com/LegacyRss?Length=4 newsdesk@globenewswire.com http://www.10gbhost.com/news-release/2021/02/05/2170929/0/en/Assembly-Biosciences-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2021-02-05T22:00:00Z 2021-02-06T08:00:13Z SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company’s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio’s common stock on February 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment.

]]>
2170929 en GlobeNewswire Inc. Assembly Biosciences, Inc. Fri, 05 Feb 2021 22:00 GMT Company Announcement
http://www.10gbhost.com/news-release/2021/02/05/2170799/0/en/Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons-on-3-4-February-2021.html Trading in Novo Nordisk shares by board members, executives and associated persons on 3-4 February 2021 2021-02-05T15:08:54Z 2021-02-06T08:00:13Z Bagsv?rd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

]]>
2170799 en GlobeNewswire Inc. Novo Nordisk A/S Fri, 05 Feb 2021 15:09 GMT Insider's Buy/Sell European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170784/0/en/Bespoke-Extracts-Welcomes-Trend-Expert-Carly-Stojsic-as-New-Director-of-Marketing.html Bespoke Extracts Welcomes Trend Expert Carly Stojsic as New Director of Marketing 2021-02-05T14:54:35Z 2021-02-06T08:00:13Z SUNNY ISLES, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (OTC Pink: BSPK), producer of high quality, hemp-derived CBD products, today announced the appointment of industry trend expert Carly Stojsic as the Company’s new Director of Marketing. Reporting directly to Bespoke CEO Danny Pollack, Stojsic will lead, guide and implement all aspects of the Company’s brand-building and product marketing strategies.

]]>
2170784 en GlobeNewswire Inc. BESPOKE EXTRACTS, INC. Fri, 05 Feb 2021 14:54 GMT Carly Stojsic, Director of Marketing, Bespoke Extracts


]]>
GlobeNewswire Inc.
Directors and Officers
http://www.10gbhost.com/news-release/2021/02/05/2170662/0/en/GBT-Announces-New-Employment-Inducement-Grants.html GBT Announces New Employment Inducement Grants 2021-02-05T13:00:00Z 2021-02-06T08:00:13Z SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.?(GBT) (NASDAQ: GBT) today announced that on?February 1, 2021, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units for an aggregate of 103,450 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

]]>
2170662 en GlobeNewswire Inc. Global Blood Therapeutics, Inc. Fri, 05 Feb 2021 13:00 GMT Company Announcement GBT Global Blood Therapeutics
http://www.10gbhost.com/news-release/2021/02/05/2170608/0/en/Hyloris-and-Purna-Female-Healthcare-announce-partnership-to-develop-novel-women-s-health-product.html Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product 2021-02-05T12:00:00Z 2021-02-06T08:00:13Z Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product

]]>
2170608 en GlobeNewswire Inc. Hyloris Pharmaceuticals Fri, 05 Feb 2021 12:00 GMT Press releases Company Announcement
http://www.10gbhost.com/news-release/2021/02/05/2170614/0/en/Zentalis-Pharmaceuticals-to-Participate-in-Two-Upcoming-Investor-Conferences.html Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2021-02-05T12:00:00Z 2021-02-06T08:00:13Z NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.

]]>
2170614 en GlobeNewswire Inc. ZENTALIS PHARMACEUTICALS Fri, 05 Feb 2021 12:00 GMT Calendar of Events
http://www.10gbhost.com/news-release/2021/02/05/2170437/0/en/Capital-Markets-Day-2021-Sanofi-progresses-on-its-strategy-to-drive-growth-across-its-businesses-and-innovation-with-emerging-leadership-in-immunology.html Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology 2021-02-05T06:30:00Z 2021-02-06T08:00:13Z Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology

]]>
2170437 en GlobeNewswire Inc. Sanofi Fri, 05 Feb 2021 06:30 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170437/0/fr/Capital-Markets-Day-2021-Progression-de-la-strat%C3%A9gie-de-Sanofi-pour-dynamiser-la-croissance-de-ses-activit%C3%A9s-et-son-innovation-et-%C3%A9mergence-d-un-leadership-en-immunologie.html Capital Markets Day 2021?: Progression de la stratégie de Sanofi pour dynamiser la croissance de ses activités et son innovation, et émergence d’un leadership en immunologie 2021-02-05T06:30:00Z 2021-02-06T08:00:13Z Capital Markets Day 2021?: Progression de la stratégie de Sanofi pour dynamiser la croissance de ses activités et son innovation, et émergence d’un leadership en immunologie???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

]]>
2170437 fr GlobeNewswire Inc. Sanofi Fri, 05 Feb 2021 06:30 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170444/0/en/Sanofi-delivered-close-to-double-digit-Q4-2020-business-EPS-1-growth-at-CER.html Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER 2021-02-05T06:30:00Z 2021-02-06T08:00:13Z Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER?

]]>
2170444 en GlobeNewswire Inc. Sanofi Fri, 05 Feb 2021 06:31 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170444/0/fr/T4-2020-Croissance-du-BNPA-des-activit%C3%A9s-1-de-pr%C3%A8s-de-10-%C3%A0-TCC.html T4 2020: Croissance du BNPA des activités(1) de près de 10% à TCC 2021-02-05T06:30:00Z 2021-02-06T08:00:13Z Croissance des ventes(2) de 4,2% et croissance du BNPA des activités de 9,8% à TCC au T4 2020??

]]>
2170444 fr GlobeNewswire Inc. Sanofi Fri, 05 Feb 2021 06:31 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170434/0/en/Hyloris-and-Purna-Female-Healthcare-announce-partnership-to-develop-novel-women-s-health-product.html Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product 2021-02-05T06:00:00Z 2021-02-06T08:00:13Z Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product

]]>
2170434 en GlobeNewswire Inc. Hyloris Pharmaceuticals Fri, 05 Feb 2021 06:00 GMT Press releases Company Announcement
http://www.10gbhost.com/news-release/2021/02/04/2170312/0/en/Zealand-Pharma-to-Host-R-D-Day-on-March-5-2021.html Zealand Pharma to Host R&D Day on March 5, 2021 2021-02-04T21:05:00Z 2021-02-06T08:00:13Z

]]>
2170312 en GlobeNewswire Inc. Zealand Pharma Thu, 04 Feb 2021 21:05 GMT Calendar of Events
http://www.10gbhost.com/news-release/2021/02/04/2170238/0/en/PRA-Health-Sciences-to-Report-Fourth-Quarter-and-Full-Year-2020-Earnings.html PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings 2021-02-04T18:01:10Z 2021-02-06T08:00:13Z RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:?PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

]]>
2170238 en GlobeNewswire Inc. PRA Health Sciences, Inc. Thu, 04 Feb 2021 18:01 GMT Calendar of Events PHARMACEUTICALS BIOTECHNOLOGY EARNINGS Contract Research Organization
http://www.10gbhost.com/news-release/2021/02/04/2170231/0/en/Monthly-information-related-to-total-number-of-voting-rights-and-shares-composing-the-share-capital-January-31-2021.html Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021 2021-02-04T18:00:00Z 2021-02-06T08:00:13Z ??????????????????????????????????????????????????????????????????????????????? ?

]]>
2170231 en GlobeNewswire Inc. Erytech Pharma S.A. Thu, 04 Feb 2021 18:00 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/04/2170231/0/fr/Information-mensuelle-relative-au-nombre-total-de-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-Janvier-2021.html Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 Janvier 2021 2021-02-04T18:00:00Z 2021-02-06T08:00:13Z ??Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au

]]>
2170231 fr GlobeNewswire Inc. Erytech Pharma S.A. Thu, 04 Feb 2021 18:00 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/04/2169902/0/en/GBT-Initiates-Expanded-Access-Protocol-for-Oxbryta-voxelotor-in-Pediatric-Patients-with-Sickle-Cell-Disease-in-the-United-States.html GBT Initiates Expanded Access Protocol for Oxbryta? (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States 2021-02-04T13:00:00Z 2021-02-06T08:00:13Z SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta? (voxelotor) in pediatric patients with sickle cell disease (SCD) has been initiated and is currently enrolling. The EAP is designed to provide access to Oxbryta prior to approval for children ages 4 to 11 years with SCD in the United States who have no alternative treatment options and are ineligible to participate in clinical trials of Oxbryta. GBT enrolled its first patient in the EAP in January 2021.

]]>
2169902 en GlobeNewswire Inc. Global Blood Therapeutics, Inc. Thu, 04 Feb 2021 13:01 GMT Health Product / Services Announcement GBT Global Blood Therapeutics
http://www.10gbhost.com/news-release/2021/02/04/2169820/0/en/Otonomy-to-Report-Fourth-Quarter-and-Full-Year-2020-Financial-Results-and-Provide-Corporate-Update.html Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update 2021-02-04T12:30:00Z 2021-02-06T08:00:13Z SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc.?(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update at 4:30 p.m. ET on February 11, 2021.

]]>
2169820 en GlobeNewswire Inc. Otonomy, Inc. Thu, 04 Feb 2021 12:30 GMT Calendar of Events otonomy OTIC OTIVIDEX hearing disorders hearing loss neurotology Meniere's Disease tinnitus
http://www.10gbhost.com/news-release/2021/02/04/2169825/0/en/Theratechnologies-Lead-Peptide-Drug-Conjugate-TH1902-Receives-FDA-Fast-Track-Designation-for-the-Treatment-of-Sortilin-expressing-Cancers.html Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment?of Sortilin-expressing Cancers 2021-02-04T12:30:00Z 2021-02-06T08:00:13Z MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

]]>
2169825 en GlobeNewswire Inc. Theratechnologies Thu, 04 Feb 2021 12:30 GMT Health
http://www.10gbhost.com/news-release/2021/02/04/2169825/0/fr/Theratechnologies-obtient-la-d%C3%A9signation-fast-track-de-la-FDA-pour-son-conjugu%C3%A9-peptide-m%C3%A9dicament-TH1902-pour-le-traitement-de-cancers-exprimant-le-r%C3%A9cepteur-de-la-sortiline.html Theratechnologies obtient la désignation ??fast track?? de la FDA pour son conjugué peptide-médicament TH1902 pour le traitement de cancers exprimant le récepteur de la sortiline 2021-02-04T12:30:00Z 2021-02-06T08:00:13Z MONTRÉAL, 04 févr. 2021 (GLOBE NEWSWIRE) -- Theratechnologies inc. (??Theratechnologies??) (TSX:?TH) (NASDAQ: THTX), une société biopharmaceutique commerciale axée sur le développement et la commercialisation de traitements innovateurs, a le plaisir d’annoncer que la Food and Drug Administration (FDA) des états-Unis a accordé la désignation ??fast-track?? pour le TH1902 comme agent unique pour le traitement de patients atteints de tumeurs solides avancées et récurrentes exprimant le récepteur de la sortiline et réfractaires au traitements standards.

]]>
2169825 fr GlobeNewswire Inc. Theratechnologies Thu, 04 Feb 2021 12:30 GMT Health
http://www.10gbhost.com/news-release/2021/02/04/2169764/0/en/Atea-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-2-Virology-Trial-of-AT-527-in-Outpatient-Setting.html Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting 2021-02-04T12:00:00Z 2021-02-06T08:00:13Z Trial to evaluate the virological efficacy of AT-527 on SARS-CoV-2 in patients with mild to moderate COVID-19]]> 2169764 en GlobeNewswire Inc. Atea Pharmaceuticals, Inc. Thu, 04 Feb 2021 12:00 GMT Health
亚洲精品私拍国产在线播放_亚洲综合区图片小说区_亚洲日本欧美日韩高观看